SC-26196

SC-26196 is a selective, potent, orally active small molecule inhibitor of fatty acid desaturase 2 (FADS2, also known as Δ6 desaturase), with an IC50 of ~0.2 µM in vitro. It blocks the conversion of linoleic acid and related polyunsaturated fatty acids to longer-chain products, including arachidonic acid, EPA, and DHA, by inhibiting the Δ6-desaturation step. SC-26196 has demonstrated anti-inflammatory properties in mouse edema models, reduces cancer stem cell populations and sphere formation in ovarian cancer cell lines, inhibits proliferation and migration of hepatocellular carcinoma cell lines, and enhances radiosensitivity in glioblastoma cell studies. It is research-grade only and not approved for clinical use[1][3][7][9][10][11][12].

Other names

α,α-Diphenyl-4-[(3-pyridinylmethylene)amino]-1-piperazinepentanenitrile2,2-diphenyl-5-[4-[(E)-pyridin-3-ylmethylideneamino]piperazin-1-yl]pentanenitrile